Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Neuropharmacology. 2014 Jul 15;86:161–173. doi: 10.1016/j.neuropharm.2014.07.006

Figure 4. Long-term exposure to WIN or AM251 in adolescence suppresses oscillations in vitro in adult mPFC and SCx.

Figure 4

(A) Experimental time course. Animals were injected with the CB1R/CB2R agonist WIN (1 mg/kg) or vehicle + the CB1R antagonist AM251 (1 mg/kg) in adolescence (P35–P55) once daily for 20 days. LFPs were recorded in vitro in slices of adult mPFC (B,C) or SCx (D,E). (B,C) Cumulative probability distributions of normalized oscillation power plotted on a log scale from LFPs recorded in mPFC of adult mice treated with vehicle (solid line) or (B) WIN (dashed line) or (C) AM251 (dashed line) from P35–P55. KS tests compared the effect of adolescent cannabinoid treatment on normalized oscillation power. (D,E) Plots as in (B,C) of LFPs from adult SCx.